NorthCrest Asset Manangement LLC Has $4.09 Million Stake in Bristol-Myers Squibb (NYSE:BMY)

NorthCrest Asset Manangement LLC lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 41.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,070 shares of the biopharmaceutical company's stock after selling 47,889 shares during the period. NorthCrest Asset Manangement LLC's holdings in Bristol-Myers Squibb were worth $4,091,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Wealthspire Advisors LLC grew its position in Bristol-Myers Squibb by 0.6% in the fourth quarter. Wealthspire Advisors LLC now owns 28,679 shares of the biopharmaceutical company's stock worth $1,622,000 after acquiring an additional 170 shares in the last quarter. Bedel Financial Consulting Inc. grew its position in Bristol-Myers Squibb by 3.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 5,690 shares of the biopharmaceutical company's stock worth $340,000 after acquiring an additional 175 shares in the last quarter. King Wealth Management Group grew its position in Bristol-Myers Squibb by 2.6% in the fourth quarter. King Wealth Management Group now owns 7,294 shares of the biopharmaceutical company's stock worth $413,000 after acquiring an additional 182 shares in the last quarter. Thoroughbred Financial Services LLC grew its position in Bristol-Myers Squibb by 1.1% in the fourth quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company's stock worth $1,004,000 after acquiring an additional 190 shares in the last quarter. Finally, Marcum Wealth LLC grew its position in Bristol-Myers Squibb by 1.0% in the first quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company's stock worth $1,177,000 after acquiring an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company's stock.

Insider Activity at Bristol-Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of Bristol-Myers Squibb stock in a transaction dated Friday, April 25th. The shares were bought at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.09% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on BMY. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price objective on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. William Blair reaffirmed a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Wall Street Zen downgraded shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Jefferies Financial Group decreased their price objective on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Bristol-Myers Squibb has a consensus rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

BMY stock traded down $0.99 during trading on Friday, hitting $49.71. 9,394,854 shares of the stock traded hands, compared to its average volume of 12,995,538. Bristol-Myers Squibb has a one year low of $39.35 and a one year high of $63.33. The stock has a market cap of $101.15 billion, a price-to-earnings ratio of -11.25, a P/E/G ratio of 2.07 and a beta of 0.38. The company has a 50 day simple moving average of $48.71 and a 200 day simple moving average of $54.73. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The firm had revenue of $11.20 billion during the quarter, compared to the consensus estimate of $10.77 billion. During the same period last year, the firm posted ($4.40) EPS. The firm's quarterly revenue was down 5.6% on a year-over-year basis. Equities analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.